alert icon Coronavirus

Now scheduling COVID-19 vaccines for ages 12+ and third doses for eligible patients
Schedule your appointment
COVID-19 vaccine FAQs

Going to a Cleveland Clinic location?
New visitation guidelines
Masks required for patients and visitors (even if you're vaccinated)

Shilpa Gupta, MD

Shilpa Gupta, MD
  • Watch Video
  • No ratings
  • 0 Patient Satisfaction Ratings
  • 0 Patient Comments
Department Hematology and Medical Oncology
Primary Location Cleveland Clinic Main Campus
Type of Doctor Adults Only
Languages English
Surgeon No
Locations Specialties & Treatments

Treatment & Services

  • Cancer
  • Cancer Center
  • Clinical Drug Trials
  • Clinical Trials
  • Experimental Therapeutics
View all 5 Treatment & Services +

Specialty in Diseases & Conditions

  • Bladder Cancer
  • Cancer Genomic Medicine
  • Cancer of Unknown Primary
  • Kidney Adenocarcinoma
  • Kidney Cancer
  • Neuroendocrine Carcinoma
  • Pelvis Cancer
  • Penile Cancer
  • Prostate Cancer
  • Testicular Cancer
View all 10 Specialties +
Insurance

Insurance

Is Cleveland Clinic Part of Your Insurance?

Review a list of accepted insurance plans for our Northeast Ohio locations or learn more about purchasing a contracted managed care plan.

View All Plans
Biography

About Shilpa Gupta, MD

Dr. Shilpa Gupta is the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic. 

Dr. Gupta obtained her Medical Degree at the Lady Hardinge Medical College in New Delhi, India and completed a residency in Internal Medicine at the University of Connecticut Health Center. She completed Hematology-Oncology fellowship at Georgetown University and Thomas Jefferson University followed by a Genitourinary Oncology Translational Research fellowship at Thomas Jefferson University. Dr. Gupta was a faculty at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida in the Departments of Genitourinary Oncology and Experimental Therapeutics from 2011 until 2015. From 2015 until 2019, she was Associate Professor and Lead for the Solid Tumor Phase 1 Program at Masonic Cancer Center, University of Minnesota. Dr. Gupta serves on the ASCO Annual Scientific Committee for Genitourinary Cancers and SITC Anti-PD-1/PD-L1 Resistance Task Force. She is also on the panel of the SITC Cancer Immunotherapy Guidelines and the International Bladder Cancer Groups core committee and Society of International Urology Innovators. 

Dr. Gupta’s research interests are novel drug development and understanding biomarkers of response and resistance to therapies in bladder cancer. Dr. Gupta has led several Investigator Initiated Trials in Genitourinary Cancers and has leadership roles in NCI trials and is Chair of an Alliance led phase 3 trial in Bladder Cancer, Co-Chair of SWOG S1206 trial in Prostate Cancer and SWOG champion of the Alliance A031701 trial in Bladder Cancer. She is Principal Investigator of 2020 Department of Defense Idea Award to study the biomarkers of response and resistance to immunotherapy in bladder cancer and Co-Principal Investigator of Department of Defense Team Translational Science Award to study immunotherapy combination strategies to overcome resistance in bladder cancer. Dr. Gupta is the Co-Chair of the Hoosier Cancer Research Network (HCRN) Genitourinary Working Group and Co-Chair of the Case Comprehensive Cancer Center PRMC committee. 

Her research work has been published in peer-reviewed journals including the Journal of Clinical oncology, Lancet Oncology, Clinical Cancer Research, European oncology, among others. She is the author for the AUA core curriculum for penile cancer and serves on the NCCN Guidelines Panel for Prostate Cancer. 

Dr. Gupta is active in several professional organizations including the American Society of Clinical Oncology (ASCO), American Urologic Association (AUA), American Association of Cancer Research (AACR), Society of Urologic Oncology (SUO), Society of Immunotherapy for cancer (SITC), Bladder Cancer Advocacy Network (BCAN), Prostate Cancer Foundation (PCF) and the European society of Medical Oncology (ESMO).

Education & Professional Highlights

Education & Professional Highlights

Appointed
2019

Education & Fellowships

Fellowship - Jefferson Medical College of Thomas Jefferson University
Genitourinary Oncology Research Fellowship
Philadelphia, PA USA
2011

Fellowship - Jefferson Medical College of Thomas Jefferson University
Hematology-Oncology
Philadelphia, PA USA
2010

Fellowship - Medical College of Wisconsin
Hematology-Oncology
Milwaukee, WI USA
2009

Fellowship - Georgetown University School of Medicine
Hematology-Oncology
Washington, DC USA
2008

Residency - University of Connecticut Health Center
Internal Medicine
Farmington, CT USA
2007

Internship - RCH Government Hospital
Faridabad, India
2001

Medical Education - Lady Hardinge Medical College
New Delhi, India
2001

Certifications

  • Internal Medicine - Medical Oncology

Specialty Interests

Genitourinary Cancers: Bladder Cancer, prostate Cancer, Kidney Cancer, Testicular Cancer

Research & Publications

Research & Publications

See publications for Shilpa Gupta, MD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Industry Relationships

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 9/20/2021, Dr. Gupta has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Gupta receives fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:

  • Pfizer, Inc.
  • EMD Serono, Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Related Videos Featuring Shilpa Gupta, MD

Related Videos Featuring Shilpa Gupta, MD

Back to Top